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Large, multidimensional cancer datasets provide a resource that
can be mined to identify candidate therapeutic targets for specific
subgroups of tumors. Here, we analyzed human breast cancer
data to identify transcriptional programs associated with tumors
bearing specific genetic driver alterations. Using an unbiased
approach, we identified thousands of genes whose expression
was enriched in tumors with specific genetic alterations. However,
expression of the vast majority of these genes was not enriched if
associations were analyzed within individual breast tumor molecular
subtypes, across multiple tumor types, or after gene expression was
normalized to account for differences in proliferation or tumor
lineage. Together with linear modeling results, these findings
suggest that most transcriptional programs associated with specific
genetic alterations in oncogenes and tumor suppressors are highly
context-dependent and are predominantly linked to differences in
proliferation programs between distinct breast cancer subtypes. We
demonstrate that such proliferation-dependent gene expression
dominates tumor transcriptional programs relative to matched
normal tissues. However, we also identified a relatively small group
of cancer-associated genes that are both proliferation- and lineage-
independent. A subset of these genes are attractive candidate
targets for combination therapy because they are essential in breast
cancer cell lines, druggable, enriched in stem-like breast cancer cells,
and resistant to chemotherapy-induced down-regulation.
breast cancer | bioinformatics | tumor biology | gene expression |
oncogene
Decades of work have led to the identification of oncogenesand tumor suppressors that, when mutated, are capable of
driving the development of cancer (1). Recent large-scale se-
quencing efforts have validated the importance of these genes in
human cancer and have expanded the panel of known recurrent
somatic alterations for many tumor types (2, 3). The observation
that cancer cells are often addicted to their driver oncogenes (4)
has motivated the development of personalized therapies targeted
directly at such genetically altered gene products, and many such
therapies have improved both survival and the overall quality of
cancer care (5, 6). However, although most targeted therapies are
initially effective, they typically have limited efficacy because of the
development of resistance. In addition, many tumors are driven by
the loss of tumor suppressors or undruggable oncoproteins, further
highlighting the need to develop strategies to identify additional
drug targets to enhance the efficacy of cancer treatments (7).
One alternative strategy is to identify genes that are not directly
genetically altered in tumors, but are nonetheless required for tu-
mor development and/or maintenance. These so-called non-
oncogene addictions (8) are also targets of numerous existing
therapeutic agents and continue to be the subject of intense in-
vestigation (9). Nononcogene targeted therapies, which include
several standard-of-care therapies (10), are often effective, but their
efficacy is usually context-dependent, making it critical to identify
biomarkers that predict which patients will respond to therapy.
Recently assembled large multidimensional genome-wide
datasets have facilitated multiplexed analyses of tumor molecu-
lar features (3, 11, 12). In particular, genetic and transcriptomic
data have been extensively used to identify functional genetic al-
terations, mechanisms by which tumor driver alterations induce
phenotypic change, or molecular signatures for the classification of
tumors (12–28). However, in most cases, the biological implications
of alteration-associated gene expression and whether or not associ-
ated genes might represent potential vulnerabilities has not been
extensively studied. Here, we analyzed The Cancer Genome Atlas
(TCGA) data to identify important contributors to variability in
breast cancer gene expression programs, with the goal of identifying
potential vulnerabilities that are specific to subgroups of breast tu-
mors. Initially, we used an unbiased approach to identify genes
differentially expressed in tumors with specific genetic alterations.
This approach highlighted the overwhelming importance of molec-
ular subtype in breast tumor gene expression profiles, and refocused
our attention on proliferation rate and tumor lineage, which are two
critical underlying factors of the subtype designation (29, 30). We
found that genetic alterations are not independently associated with
broad gene expression programs when proliferation and lineage are
taken into account. Building on these findings, we explored the
contribution of proliferation to differences in gene expression in
matched pairs of normal and tumor tissue from diverse cancer types,
and found that most genes differentially expressed in tumors cor-
related with the proliferative signature of the tumors. However, we
also identified cancer-associated genes from multiple tumor lineages
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whose expression is not linked to the proliferative state of the tumor,
suggesting that these genes are both proliferation- and lineage-
independent. The expression of many of these genes is maintained
after chemotherapy treatment and is enriched in stem-like cancer
cells, leading us to propose that the subset of these genes that are
essential and druggable are candidate targets for combination
therapies.
Results
Gene Expression Associated with Genetic Alterations, Lineage, and
Proliferation. To identify transcriptional programs associated
with recurrent genetic alterations in breast tumors, we analyzed
DNA sequence, copy number variation, and RNAseq data from
the TCGA breast cancer dataset (11). We defined genetic alter-
ations as nonsilent somatic mutations, amplifications, or deletions,
and performed differential expression analyses independently for
each alteration. Any gene with significantly higher or lower mean
expression in tumors with a genetic alteration relative to tumors
without that alteration were considered associated with the alter-
ation (termed gene:alteration association). We did not require
gene:alteration associations to be specific to a given alteration,
allowing for the identification of shared transcriptional programs
among alterations with similar predicted modes of action (e.g.,
PIK3CA amplifications, PTEN deletions, and PIK3CA mutations).
To reduce false positives resulting from coamplification or code-
letion with copy number variations, we eliminated associations if a
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Fig. 1. Genes and pathways associated with common genetic alterations in breast tumors. (A) Bar graph of the number genes associated with the 10most common
genetic alterations found in the entire TCGA breast dataset (“all-breast,” black), within any of the four major breast molecular subtypes (“within-subtype,” red) or
after subtype-centering (“subtype-centered,” blue). (B–F) GeneGo Pathway Maps (circles) and genetic alterations (rounded rectangles) are connected by lines
representing significant positive (red lines) or negative (blue lines) enrichment in mRNA levels in tumors bearing the indicated genetic alteration. Green lines in-
dicate new pathways not identified in the all-breast enrichment. Pathways related to proliferation or DNA damage are indicated in red or orange, respectively.
Threshold for statistical significance was false discovery rate corrected; P < 0.05, hypergeometric test. Pathway enrichment results are depicted from the all-breast
(B), subtype-independent (C), proliferation-normalized all-breast (D), proliferation-normalized within-subtype (E), and the ESR1-normalized all-breast (F) analyses.
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gene was on the same chromosome arm as the associated alter-
ation and coamplified or codeleted in more than one third of the
samples. Because the different subgroups of breast tumors can be a
confounding factor in gene expression association studies (10, 31),
we performed this analysis both on the entire TCGA breast cancer
dataset as well as within each of the four major molecular subtypes
of breast tumors (HER2+, basal, luminal A, and luminal B) (29).
Of the 14,209 expressed genes and 52 genetic alterations analyzed,
we identified 21,890 gene:alteration associations in the entire all-
breast dataset (Bonferroni-corrected P < 0.05, Welch’s t test; Fig.
1A and Fig. S1A and Dataset S1A). This number was reduced by
94.8% (1,143 associations identified) when the analyses were
performed within each individual molecular subtype (Fig. 1A
and Fig. S1A and Dataset S1B). Because the within-subtype
analyses also significantly reduced sample size and statistical
power, we also used a subtype-centering method to normalize for
subtype-dependent gene expression without reducing sample
size. This revealed a similar 93.0% reduction in gene:alteration
associations (Fig. 1A and Fig. S1A and Dataset S1C), suggesting
that the reduced number of associations in the within-subtype
analysis was not merely a result of decreased statistical power,
but was a result of the strong confounding influence of molecular
subtype on gene expression analysis of breast tumors. Five
hundred seventy-nine gene:alteration associations were identi-
fied as being subtype-independent by both approaches (Fig. S1B
and Dataset S1C).
To understand the biological implications of the gene:alter-
ation association findings from the all-breast and subtype-
independent analyses, we performed GeneGO enrichment
analysis on the genes associated with the 10 most common al-
terations. In the all-breast dataset, the majority of the genetic
alteration-associated pathways are found in a large cluster of
shared pathways that are positively associated with a group of six
alterations (TP53 mutation; MYC, ERBB2, and PIK3CA ampli-
fications; and PTEN and RB1 deletions), and negatively associ-
ated with three alterations (PIK3CA, CDH1, and MAP3K1
mutations; Fig. 1B and Dataset S2A). This shared cluster consists
largely of pathways related to cell cycle control, DNA damage,
and cellular proliferation. As expected, there is a significant re-
duction in the number of enriched pathways when the analysis is
performed on the subtype-independent associations; however, this
analysis revealed several interesting subtype-independent genetic
alteration-associated genes/pathways (Fig. 1C and Dataset S2B).
Among the most interesting is the association ofMYC amplification
with elevated levels of numerous protein folding genes (HSP105,
HSP90AA1, HSP90AB1, STIP1, PTGES3, and FKBP4), suggesting
that MYC-amplified tumors might be sensitive to agents targeting
the protein folding machinery. In addition, PIK3CA mutant tumors
show enrichment of WNT signaling genes (TCF7L2,WNT5A), and
CDH1 mutant tumors have higher HGF and IL6 pathway genes.
Although there was a significant reduction in the number of
proliferation-related pathways in the subtype-independent
pathway analysis compared with the all-breast analysis, several
genetic alterations were associated with proliferation-related
pathways within molecular subtypes (Fig. 1C and Dataset S2B).
Although proliferation-dependent gene expression has been
shown to play an important role in pathway enrichment analyses
(10, 32, 33) and breast molecular subtype designation (29, 30,
34), there has not been a systematic analysis of the overall
contribution of proliferation-dependent gene expression to ge-
netic alteration-associated gene expression. To accomplish this,
we performed a normalization for gene expression that can be
attributed to differences in proliferation (32) and reanalyzed the
previously identified gene:alteration associations. In the all-
breast dataset, proliferation normalization resulted in a 76%
reduction in associations and a dramatic 86% reduction in
enriched pathways (Fig. 1D and Fig. S2A and Datasets S1D and
S2C), despite only reducing the total variance in gene expression
by 7% (Fig. S2B). Proliferation normalization also had a large,
but muted, effect on the within-subtype associations and pathway
enrichment (Fig. 1E and Fig. S2C and Datasets S1E and S2D).
This reduced effect likely reflects the importance of proliferation
in subtype designation (29, 30, 34) and the likelihood that the
within-subtype analysis itself accounts for differences in gene ex-
pression resulting from proliferation. Interestingly, proliferation
normalization uncovered gene and pathway associations that were
not statistically significant in the uncorrected dataset (Fig. 1 D and
E and Fig. S2D and Datasets S1E and S2 C and D), revealing
potentially interesting associations that are masked by the domi-
nant effects of proliferation, as we have previously observed (10).
For example, proliferation normalization revealed that the
O-glycan and cholesterol biosynthesis pathways are associated
with MYC amplification and MAP3K1 mutation, respectively
(Dataset S2 C and D).
In addition to proliferation, tumor cell lineage may influence
our analyses of genetic alteration associations, given that the
genetic alterations we tested are disproportionally found within
specific lineages and lineage is highly related to molecular sub-
type (11). The most fundamental way to separate breast tumors
based on lineage is by distinguishing tumors that are positive or
negative for expression of the estrogen receptor (ER) (35). To
understand the effect of lineage on genetic alteration-associated
gene expression, we performed a normalization using ESR1
mRNA expression as a lineage marker, similar to the previously
used proliferation normalization method that used a proliferation
gene signature. In the all-breast dataset, ESR1 normalization re-
duced gene expression variance by only 9.6% (Fig. S2B), but
resulted in a 67% decrease in associations and an 18% reduction in
enriched pathways (Fig. 1F and Fig. S2A and Datasets S1F and
S2E). This suggests that genetic alteration associations are influ-
enced by differences in gene expression caused by the distinct
lineages of breast tumors and the uneven distribution of genetic
alterations within these lineages, whereas enriched pathways are
more dependent on differences in proliferation.
To directly assess the predictive power of proliferation, line-
age, and genetic alterations on gene expression, we generated a
series of linear models for each expressed gene in the breast
dataset. In univariate models, we found that proliferation sig-
nature score (32), proliferation status, ESR1 mRNA, and clinical
ER status were all generally better predictors of gene expression
than any of the genetic alterations, having higher mean coeffi-
cients of determination (r2; Fig. S2E and Dataset S3A; P < 0.05,
Student’s t test). Next, we determined whether the addition of
genetic alteration information improves the performance of
multiple regression models that take into account both pro-
liferation and lineage (models of gene expression based on
proliferation + ESR1 vs. proliferation + ESR1 + genetic alter-
ation) (Dataset S3B). Plotting model improvement (Δr2) for
each gene with significantly increased goodness of fit (P < 0.05,
likelihood ratio test of nested models) reveals that the majority
of models are not more accurate when genetic alteration in-
formation is added, and most of those that are improved are only
minimally better (Fig. 2A and Dataset S3B). Further, the vast
majority of the genes with high Δr2 values are coamplified or
codeleted with the driver gene (Fig. 2A, indicated in red, Dataset
S3B). These results, which we independently validated using
METABRIC data (12) (Fig. 2B and Dataset S4), support our
finding that genetic alterations are not strong independent pre-
dictors of gene expression in breast tumors when differences in
gene expression resulting from lineage, proliferation, and
coamplification/codeletion are taken into account.
As an additional test of the influence of genetic alterations on
gene expression, we determined the extent to which our gene:
alteration association findings in breast tumors were found in
10 other tumor types (35). Only 6.9% (1,453) of the gene:alter-
ation associations identified in analysis of the 10 most common
E11278 | www.pnas.org/cgi/doi/10.1073/pnas.1714877115 Selfors et al.
alterations and all-breast samples were identified in one or more
additional cancer types, and only 0.8% (166) were identified in
two or more additional cancer types (Fig. 2C and Dataset S5A).
The subtype-independent gene:alteration findings were only
slightly more likely to be validated, with 8.4% (47) of the gene:
alteration associations identified in one other cancer type and
2.9% (16) identified in two or more additional cancer types (Fig.
2D and Dataset S5B). Even alterations that are commonly found
across tumor types (i.e., MYC amplification and TP53 mutation)
had fewer than 10 associated genes (6 and 8, respectively) that
validated in two or more cancer types, demonstrating that
alteration-associated gene expression found in breast tumors is
not strongly recapitulated in other tumor types. To improve
statistical power, we merged the 10 additional tumor types and
analyzed this pan-cancer dataset together, where we found that
9.6% (2,019) of the all-breast and 17.6% (99) of the subtype-
independent findings were validated (Fig. 2 E and F and Dataset
S5 C and D). These findings demonstrate that although the vast
majority of our gene:alteration associations are specific to breast
tumors, subtype-independent associations are more likely to be
found in other tumor types.
All these analyses support the conclusion that the transcrip-
tional programs associated with specific genetic alterations are
likely to be highly context-dependent, and most are secondary to
proliferative states and/or lineages with which the genetic alter-
ations are associated.
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Fig. 2. The contribution of genetic alterations to gene expression beyond proliferation, tumor lineage, and in multiple tumor types. (A and B) Multiple linear
regression models depicting the contribution of genetic alterations to gene expression when proliferation and ESR1 are taken into account. Each point rep-
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Identification of Proliferation- and Lineage-Independent Cancer
Genes. Although the relatively small group of proliferation- and
subtype-independent associations identified here warrant addi-
tional investigation, we were interested in developing a direct
informatics pipeline to identify genes that are more generally
associated with the cancer state independent of proliferation and
cell lineage, because these may represent more attractive targets
for therapeutic intervention.
To accomplish this, we first analyzed TCGA RNAseq data
from 10 diverse tumor types with patient-matched tumor and
normal data, where we detected the expected increase in pro-
liferation scores in tumors relative to normal (Fig. 3 and Fig. S3
A–E, box plots). We next compared gene expression differences
between tumor and normal samples and the degree to which the
expression level of each gene correlates with proliferation scores
in each of the 10 tumor types (Fig. 3 and Fig. S3 A–E, volcano
plots and histograms). Indeed, genes elevated in tumors are
more likely to be positively correlated with proliferation, whereas
genes at lower levels are more likely to be negatively correlated
with proliferation.
In these analyses we also identified a subgroup of genes that
are exceptions to this trend and are higher in tumors but not
positively correlated with proliferation (Fig. 3 and Fig. S3 A–E,
volcano plots and histograms). These genes could be specifically
up-regulated in tumors independent of their proliferative status
or more highly expressed because the tumor cell of origin is not
abundant in bulk normal tissue, and because their expression is
elevated, their protein products might offer a potential thera-
peutic window for cancer therapy. To evaluate the lineage-
dependence of the expression of these genes, we identified
genes whose expression is elevated in tumors but not positively
correlated with proliferation across multiple tumor types. Of the
2,972 genes that are elevated in tumors relative to normal in five
or more cancer types (termed TA for tumor-associated, Dataset
S6A), 363 were not positively correlated with proliferation
(termed TANP for tumor-associated nonproliferation; Dataset
S6B). Pathway enrichment of the TANP genes revealed three
pathways, two of which (“Chondroitin sulfate and dermatan
sulfate metabolism” and “Cell adhesion_Cell-matrix interac-
tions”) were specifically enriched in the TANP set, and one
(“Transcription_Chromatin modification”) that was enriched in
both the TANP and TA gene sets (Fig. 4A and Dataset S6 C and
D). The two TANP-specific pathways, which include genes in-
volved in extracellular matrix interactions, represent tumor-
associated pathways that would not be detected by methods that
do not take into account the dominant influence of proliferation-
associated gene expression on pathway enrichment analysis.
The TANP genes might be of particular interest as potential
targets for combination cancer therapies, as slowly proliferating
or quiescent tumor cells can be resistant to many chemotherapies
(10, 36). On the basis of their lack of proliferation correlation,
TANP genes would be predicted to be less likely to be down-
regulated by chemotherapies that inhibit proliferation, and
therefore may be better candidates for combination therapy. To
test this idea, we analyzed gene expression data from tumor
specimens that were harvested before and after one round of
chemotherapy (37). Focusing on data from patients who respon-
ded to therapy to select for data in which there was effective drug
delivery, we found that TANP genes are more than five times less
likely to be down-regulated by chemotherapy than TA genes that
are associated with proliferation (TAP genes; risk ratio = 5.1; P =
1.9 × 10−100, Fisher’s exact test; Fig. 4 B and C and Fig. S3F and
Dataset S6B). This suggests that despite the many confounding
variables associated with chemotherapy treatment of patient
tumors, proliferation correlations predict gene expression re-
sponses to chemotherapy. This places an emphasis on TANP
genes as potential targets for combination with chemotherapy, as
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Fig. 3. Proliferation-dependent and proliferation-independent gene ex-
pression in tumors and matched normal samples. Proliferation-dependent
expression in tumor and matched normal samples from TCGA breast (BRCA,
n = 113) (A), lung adenocarcinoma (Adeno.; n = 57) (B), lung squamous
(Squam.; n = 51) (C), thyroid (n = 59) (D), and head and neck (n = 42) (E)
datasets. Box plots show the proliferation scores of matched tumor and
normal samples. Lines connect samples from the same patient, and box plot
summarizes the data. Volcano plots represent the gene-level log-fold
change of tumor vs. normal (x axis) and −log(P) (y axis) where P is derived
from paired Welch’s t tests. Each data point represents a gene and is colored
according to its correlation with proliferation, where red indicates a positive
correlation and blue indicates a negative correlation. *P > 0.05 paired
Welch’s t test. Histograms are the degree to which genes correlate with the
proliferation score. The black line is all expressed genes, and the red line is
the genes that are up in tumors relative to normal.
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Fig. 4. Proliferation- and lineage-independent pathways and genes. (A) Venn diagram of GeneGo pathways that are enriched in genes elevated in tumors
relative to normal in breast and four additional tumor types (TA genes, peach), and the subset of these genes that are proliferation-independent (TANP
genes, green). Table lists the TANP-enriched pathways and genes. (B) Effect of chemotherapy on gene expression. Heat map represents the fold change (log2
ratios) in mRNA levels pre- and postchemotherapy treatment for TAP and TANP genes. Red indicates higher expression after chemotherapy treatment, and
blue indicates lower expression. (C) Differential effect of chemotherapy on gene expression of proliferation-dependent and proliferation-independent genes.
Box plot shows the fold change in mRNA (log2 ratio) before and after chemotherapy of TAP (n = 509) and TANP (n = 320) genes. *P < 0.05, Student’s t test.
(D) Gene expression in ALDH+/− cells. Heat map represents the fold change (log2 ratios) in TAP and TANP gene expression in ALDH
+ vs. ALDH− breast tumor
cells. (E) Gene expression of proliferation-dependent and proliferation-independent genes in ALDH+ cells relative to ALDH− cells. Box plot shows the fold
change in mRNA (log2 ratio) of TAP (n = 555) and TANP (n = 343) genes. *P < 0.05, Student’s t test. (F) Table lists the TANP genes that are druggable, essential
in shRNA drop-out screens, not down-regulated by chemotherapy, and enriched in ALDH+ stem-like cancer cells.
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their expression is more likely to be maintained throughout
treatment.
We next investigated the expression of the TANP genes in
stem-like cancer cells, a subpopulation of tumor cells that are
also implicated in chemoresistance (38, 39). We found that 93%
of the TANP genes were either higher or not significantly dif-
ferent in ALDH+ breast cancer cells relative to ALDH− cells,
and were 3.7 times more likely than the TAP genes to be
expressed at higher levels in ALDH+ cells (risk ratio = 3.7; P =
0.000342; Fig. 4 D and E and Dataset S6B). These data suggest
that the TANP genes are more likely to be elevated and stably
expressed in cells with stem/progenitor properties, which are
generally more resistant to chemotherapy. Of the 363 TANP
genes, 12 are essential in shRNA screens (40), druggable
(10 with currently available inhibitors) (41), unchanged by che-
motherapy treatment, and enriched in stem-like cancer cells, and
are therefore the most attractive potential targets for combina-
tion therapy in our study (Fig. 4F and Dataset S6B). They consist
of four kinases [CSNK1A1, DDR1, EIF2AK3, and ERBB3 (in-
active)], three proteases (CTSB, MMP14, and PLAU), two en-
zymes involved in N-glycan synthesis (MAN1B1 and NEU1), two
enzymes implicated in chromatin remodeling (HDAC8 and
TLE3), and one protease-activated GPCR (F2R).
Discussion
The ability to directly target the protein products of mutated
driver oncogenes is a landmark accomplishment in cancer re-
search. However, single-agent targeted therapies generally are
not curative because of the acquisition of drug resistance (5–7).
This highlights the importance of developing combination ther-
apies that prevent recurrence, and the need to identify additional
nononcogene targets or contexts in which they might be most
effective. Here, we used an unbiased computational method to
analyze genes that are differentially expressed in breast tumors
with distinct genetic alterations. This analysis revealed that there
are relatively few genes that are specifically associated with dis-
tinct genetic alterations. Rather, gene expression variation as-
sociated with specific genetic alterations could be explained by
two primary factors: proliferation and tumor lineage. Building on
these findings, we explored the effect of proliferation on cancer-
associated gene expression and identified putative lineage- and
proliferation-independent genes that are consistently higher in
diverse tumor types. Further, because these genes behave as their
proliferation correlation predicts and remain highly expressed
after chemotherapy treatment, they represent attractive candidate
targets for combination therapies.
Previous analyses have suggested that proliferation and line-
age are important contributors to the molecular subtype desig-
nation of breast tumors (29, 30). In addition, numerous reports
have identified other gene expression signatures that are asso-
ciated with specific genetic alterations in breast and other can-
cers (12, 13, 18, 22, 26, 27). Here, we performed a simplified and
unbiased analysis that identified proliferation and tumor lineage
as more dominant determinants of breast cancer gene expression
than genetic alterations. On the basis of these analyses, we con-
cluded that the specific effect of the most common genomic al-
terations is negligible for the majority of genes, other than those
that are coamplified or codeleted. This conclusion is particularly
surprising, considering that proliferation and lineage each account
for less than 10% of the total variance in gene expression in tu-
mors, leaving a large amount of gene expression variability un-
explained by these fundamental factors. It is important to note that
the small group of potential alteration-specific associated genes
detected by our approach, as well as the genes identified by other
groups using more complex analytical methods, are likely to be
biologically important and warrant additional study.
Three of the genetic alterations analyzed here (MYC, GATA3,
and TP53) encode transcription factors that might be predicted
to have specific transcriptional signatures; however, we did not
detect such enrichment in tumors carrying these genetic alter-
ations. There are several potential explanations for this finding.
First, direct transcriptional targets of MYC may not be specifi-
cally enriched in tumors with MYC amplification because MYC
protein can be directly activated by signaling pathways induced
by many oncogenes, making it likely that MYC is active in most
proliferating tumor cells regardless of whether the MYC gene is
amplified. Therefore, our proliferation correction method may
“remove” many direct targets of MYC because they are activated
in most highly proliferating tumors. Similarly, TP53 mutations
typically result in loss of function for p53’s role in cell cycle arrest
(42); thus, although mutations in TP53 result in changes in
transcription of proliferation-associated genes, these would be
lost by proliferation normalization. Finally, GATA3 is an im-
portant transcription factor involved in mammary gland differ-
entiation and is required for the growth of ER+ breast cancers
(43). Therefore, it is likely that our proliferation and lineage
correction methods remove most genes directly regulated by
these transcription factors because they are inherently linked to
proliferation and/or lineage, regardless of their mutation status.
In contrast, mutations in the NRF2 axis, which controls the re-
sponse to oxidative stress, are associated with specific tran-
scription signatures in lung, head and neck, and bladder tumors
(44, 45). Unlike MYC and p53, however, NRF2 does not appear
to be commonly activated in diverse cancer types, and only a
subset of NRF2-dependent genes are redundantly regulated by
other transcription factors. Therefore, association-based studies
can be effective at identifying the direct oncogenic effects of
some genetically altered genes.
Although our studies have revealed that the underlying genetic
alterations are not broadly or independently predictive of gene
expression in tumors, the genetic background of a cell has been
shown to determine how cells respond to therapeutic intervention
(46–48). For example, tumors harboring mutations in the BRCA1/
2 genes are more sensitive to poly(ADP ribose) polymerase in-
hibitors (49), an observation that is now taken advantage of in the
clinic for ovarian cancer (50). Interestingly, although genetic al-
terations do not dramatically affect gene expression, gene ex-
pression signatures are predictive of response to chemotherapy
(10). Thus, both genetic alterations and gene expression patterns
can be predictive of therapeutic response even if they may not be
highly related to each other.
Many current therapies are limited in effectiveness because of
the reduced sensitivity of quiescent cells. For example, standard-
of-care chemotherapies effectively kill proliferating tumor cells
(10, 51), whereas slower cycling cells, such as stem-like cancer
cells, can be resistant (38). In addition, many therapies have
cytostatic effects, and tumor cells can reinitiate proliferation
after treatment ends (52). In these contexts, the ideal targets for
combination therapy would be proliferation-independent, drug-
gable proteins that are not down-regulated by primary treatment
and are expressed in drug-resistant cells. By removing the
dominant effects of proliferation on tumor-associated gene ex-
pression, we have identified genes that meet these criteria. Al-
though further investigation will establish their effectiveness,
several of these genes (CTSB, DDR1, ERBB3, HDAC8, MMP14,
NEU1, and PLAU) have been validated as combination therapy
targets in cancer models (53–58), including two (ERBB3 and
PLAU) in clinical trials in combination with chemotherapy (59,
60). Notably, many of these genes are implicated in extracellular
matrix remodeling (CTSB, DDR1, MMP14, and PLAU), and
multiple studies have identified mechanisms by which extracel-
lular matrix signaling mediates resistance to apoptotic stimuli
(61–63), demonstrating that our method can identify attractive
targets for combination therapy.
Together, our results suggest that phenotypic programs are
critical determinants of gene expression patterns in tumors that
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confound analyses of the association of gene expression with
genetic alterations. By identifying tumor-associated genes that
are independent of two dominant confounding programs (pro-
liferation and tumor lineage), we have identified genes that
warrant further analysis as therapeutic targets.
Methods
Identification of Gene:Alteration Associations. Genes associated with recurrent
somatic genetic alterations were identified in TCGA data (2015-02-24 data-
freeze) obtained from the University of California, Santa Cruz cancer
browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). For copy
number associations, RNAseq normalized expression counts [HiSeqV2,
log2(x + 1) transformed RNAseq by expectation maximization (RSEM) nor-
malized count] from amplified or deleted tumors (GISTIC scores of 2 and −2,
respectively) were compared with tumors diploid at that locus (GISTIC score
0). Genes on the same chromosome arm as copy number alterations were
eliminated if they were coamplified or codeleted with the genetic alteration
in more than 33% of tumors. For mutation associations, a tumor was con-
sidered mutated at a given locus if it had a somatic alteration call of 1 in the
PANCAN AWG data. Low-expression genes, defined as >5% tumors with
0 counts or mean counts <4, were removed from the analysis. A minimum of
five samples with a genetic alteration was required for all statistical tests.
Statistical significance was determined using the t-test function in version
3.2.2. Bonferroni-corrected P < 0.05 was the threshold for statistical signifi-
cance. A pan-cancer dataset was compiled from 10 TCGA cohorts (BLCA,
COADREAD, GBM, HNSC, LGG, LUAD, LUSC, OV, PRAD, and UCEC). The
RNAseq gene expression values [log2(x + 1) transformed RSEM normalized
counts] in the merged set were median centered within each cohort. For data
from the Molecular Taxonomy of Breast Cancer International Consortium,
normalized gene expression data, copy number data, and paired clinical feature
data were obtained from the publicly available European Genome-phenome
Archive (IDs EGAD00010000210 and EGAD0001000021) (12, 64).
Pathway Enrichment.Whole-genome enrichment analysis was performed using
MetaCore (GeneGo; Thomson Reuters). The background list for the breast
analysis was the 14,209 genes that passed a low-expression filter. The default
GeneGO background list was used for enrichment of genes frommultiple cancer
types. Pathway depictions were generated with Cytoscape_v2.6.3.
Molecular Subtyping TCGA Breast Tumors. RNAseq normalized expression counts
were subjected to the PAM50 classifying function (https://genome.unc.edu/
pubsup/breastGEO/). To account for the fact that the PAM50 training set is
∼50% ER−, confirmed ER− samples were randomly subsampled for an equal
number of ER+ samples. The median of the subset was calculated and assigned
to the PAM50 calibrationParameters argument. ER status (ER+/−) was extracted
from TCGA clinical data files.
Linear Modeling. Linear regression models were built for each gene using
normalized mRNA expression values as the outcome variable and proliferation
score (32), ESR1 mRNA level, or genetic alterations [binary indicator variables
representing amplified or deleted tumors (GISTIC scores of 2 and −2, re-
spectively) and samples diploid at that locus (GISTIC score 0)] as predictors. The
lm function from the R stats package was used for all modeling. The lrtest
package was used to carry out likelihood ratio tests of nested models. The
frequency of coamplification and codeletion was calculated for genes on the
same chromosome arm as the recurrent breast alteration, using the Org.Hs.eg.
db annotation package. Genes with no chromosomal location in Org.Hs.eg.db
were withheld from the Δr2 figure.
Proliferation and Lineage Correction. To correct for proliferation and ESR1, a
linear model was constructed using proliferation scores or ESR1 RNA-Seq
mRNA levels for each sample fitted to the expression of each gene using
the lm function in R. Each expression measurement was then substituted by
the sum of its residual and mean expression across the dataset. This cor-
rection method is the same as the proliferation correction that has been
previously published (32). Total variance in gene expression was calculated
by summing the variance for each expressed gene before and after pro-
liferation or lineage correction.
Expression Microarray Analysis. Data from the Gene Expression Omnibus were
analyzed in R, using the GEOquery package. To assess the effect of che-
motherapy on gene expression, log2 fold change values were calculated
from RMA-processed expression values from pretreated (bl) and paired
treated samples (c2) of patients (GSE18728). Only patients who responded to
chemotherapy (response category: R) were analyzed. To evaluate expression
in stem-like cancer cells, log2 fold change values (ALDH
+/ALDH−) were cal-
culated from RMA-processed expression values (GSE52327).
Box plots, correlation scatterplots, and their associated P values were gen-
erated in JMP Pro-11.0.0. Box plots are derived from the median (vertical line
within box), the interquartile range (ends of the box), and the first or third
quartile ±1.5 * interquartile range (whiskers). Clustering was performed in
Cluster 3.0, using average linkage and Pearson’s correlation (uncentered). Venn
diagrams were generated with Venny 2.1 (bioinfogp.cnb.csic.es/tools/venny/).
Statistics. Bonferroni-corrected two-tailed Welch’s t tests were used to
identify differences in gene expression in tumors bearing specific genetic
alterations. Paired two-sample t tests were used to compare matched tumor/
normal, chemotherapy treated/untreated, and ALDH+/− samples. For micro-
array data, unpaired two-tailed Student’s t tests were performed. Pearson’s
correlation coefficients and P values were calculated for linear correlation
analysis. The statistical tests for GeneGO pathway and TA/TANP gene en-
richment analysis were false discovery rate-corrected hypergeometric tests
and Fisher’s exact tests, respectively. For all statistical tests, the threshold for
statistical significance was set at 0.05.
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